Videos

Neurology News Network for the week ending July 29, 2023. [WATCH TIME: 4 minutes]

The associate research professor of neurobiology at Duke University discussed an innovative epigenome editing approach that shows promising prospects for patient improvement, disease prevention, and potential use in Alzheimer disease prophylactic work. [WATCH TIME: 3 minutes]

The chief executive officer at INmune Bio discussed a unique approach from a phase 1 study targeting neuroinflammation in the brain to improve cognitive abilities and maintain memory. [WATCH TIME: 5 minutes]

The chief medical officer at Athira Pharma talked about an exploratory phase 2 trial that showcased the correlation between biomarkers for Alzheimer disease hallmarks and neuroinflammation. [WATCH TIME: 5 minutes]

A duo of experts provide insight on various topics related to the advances in treatment options, diagnosis of the disorder, role of genetics, and potential future research and gene therapies.

Amy Perrin Ross, APN, Patricia Melville, NP-C, Aliza Ben-Zacharia, PhD, DNP, ANP-BC, and John Kramer, PA-C share their advice for facilitating uptake of biosimilars in clinical practices.

Advanced practice providers share how to discuss biosimilars with patients and what resources might be useful for education on biosimilars.

Amy Perrin Ross, APN, Aliza Ben-Zacharia, PhD, DNP, ANP-BC, and John Kramer, PA-C share strategies for implementing biosimilars in clinical practice.

The postdoctoral researcher at The University of Texas Health Science Center at San Antonio talked the gut microbiome and neurological disorders, focusing on the potential role of gut microbiota imbalance in the pathogenesis of conditions like Alzheimer disease. [WATCH TIME: 5 minutes]

Krzysztof Selmaj, MD, PhD, wraps up this series highlighting strategies for educating patients with relapsing-remitting multiple sclerosis (RRMS) about sphinogine-1-phospate (S1P) receptor modulators.

The clinical research associate at the University of Texas Health Science Center at San Antonio discussed a study that explores the relationship between cognitive function and gut microbiome structure in middle-aged adults from the Framingham Heart Study cohort. [WATCH TIME: 4 minutes]

Krzysztof Selmaj, MD, PhD, presents the key results on the safety of other sphinogine-1-phospate (S1P) receptor modulators, such as fingolimod and ponesimod, in the treatment of multiple sclerosis (MS).

Krzysztof Selmaj, MD, PhD, presents the results of a pooled safety study of ozanimod as treatment for relapsing-remitting multiple sclerosis (RRMS).

Krzysztof Selmaj, MD, PhD, provides key clinical considerations when switching patients with multiple sclerosis (MS) to sphinogine-1-phospate (S1P) receptor modulator treatment.

Krzysztof Selmaj, MD, PhD, provides his clinical expertise on strategies to monitor patients with relapsing-remitting multiple sclerosis (RRMS) taking sphinogine-1-phospate (S1P) receptor modulators.

Krzysztof Selmaj, MD, PhD, discusses the side effects of sphinogine-1-phospate (S1P) receptor modulators, highlighting particular adverse events clinicians should be aware of when treating multiple sclerosis (MS).

Krzysztof Selmaj, MD, PhD, explains the tissue selectivity of sphinogine-1-phospate (S1P) receptor modulators and the clinical considerations that arise when treating multiple sclerosis (MS).

Krzysztof Selmaj, MD, PhD, discusses the treatment landscape for relapsing-remitting multiple sclerosis (RRMS) and where sphinogine-1-phospate (S1P) receptor modulators fit in.

The researcher in the department of neurochemistry at the University of Gothenburg in Sweden discussed bloodspot cards as a promising method for collecting blood samples in Alzheimer disease research. [WATCH TIME: 4 minutes]

The genetic epidemiologist at the University of Pennsylvania talked about a collaboration of sites and analysis groups across the US to create a vast collection of genetic data on patients living with Alzheimer disease. [WATCH TIME: 5 minutes]

Neurology News Network for the week ending July 22, 2023. [WATCH TIME: 3 minutes]

The associate professor of neuroscience at Lund University in Sweden discussed findings from a study of a new blood test examining biomarkers which demonstrated a high accuracy in identifying Alzheimer disease pathology. [WATCH TIME: 5 minutes]

The research assistant professor, pathology and laboratory medicine, University of Pennsylvania, talked about the ongoing research in her lab on understanding the mechanisms and consequences of TDP-43 aggregation in Alzheimer Disease. [WATCH TIME: 4 minutes]

The associate professor of neurochemistry at the University of Gothenburg in Sweden talked about a pilot study that explored the potential of finger prick tests to remotely collect blood and provide reliable biomarker results for Alzheimer disease diagnosis. [WATCH TIME: 5 minutes]

In this episode of MEDcast, expert geriatric psychiatrists explore the urgent need for effective diagnostic methods that can detect Alzheimer’s disease at an early stage. We will discuss blood-based biomarkers and other advancements that can help screen Alzheimer’s disease non-invasively and early in the disease course.

The director of research for internal medicine and geriatrics at Indiana University School of Medicine provided perspective on ways to effectively streamline cognitive screening in timely and accurate manor. [WATCH TIME: 4 minutes]

The neurologist in the Danish Dementia Research Center at Rigshospitalet in Copenhagen, Denmark, discussed a cohort study that examined the association between opioid use and the risk of mortality in an older patient population living with dementia. [WATCH TIME: 5 minutes]

John Kramer, PA-C, Patricia Melville, NP-C, and Amy Perrin Ross, APN identify challenges in accessing biosimilars in clinical practice.

Aliza Ben-Zacharia, PhD, DNP, ANP-BC and Amy Perrin Ross, APN discuss differences between biologic and biologic natalizumab phase 3 trials.

The professor in the department of internal medicine at RUSH Medical College talked about estimating the prevalence of Alzheimer disease to uncover the variability in disease prevalence at a micro-level and its implications for public health programs. [WATCH TIME: 5 minutes]